E-LIB Suche - Ergebnisse für: Dranitsaris, G.

1

HPR70 Therapeutic Preference for Alzheimer'S Disease Treatm..:

Dranitsaris, G. ; Zhang, Q. ; Mu, L....
Value in Health. 26 (2023) 6 - p. S223-S224 , 2023

Link: https://doi.org/10.1016/..

2

RWD137 A Real-World Comparative Effectiveness Analysis of F..:

Dranitsaris, G. ; Peevyhouse, A. ; Wood, T....
Value in Health. 26 (2023) 6 - p. S387 , 2023

Link: https://doi.org/10.1016/..

3

An economic analysis comparing health care resource use and..:

Montazeri, K. ; Dranitsaris, G. ; Thomas, JD....
Urologic Oncology: Seminars and Original Investigations. 39 (2021) 12 - p. 834.e1-834.e7 , 2021

Link: https://doi.org/10.1016/..

4

CLINICAL RESEARCH:

Riazi, S. ; van den Bersselaar, L. ; Islander, G....
Neuromuscular Disorders. 31 (2021) - p. S49 , 2021

Link: https://doi.org/10.1016/..

5

A randomized trial of individualized versus standard of car..:

Clemons, M. ; Dranitsaris, G. ; Sienkiewicz, M....
The Breast. 54 (2020) - p. 278-285 , 2020

Link: https://doi.org/10.1016/..

6

Lanreotide vs octreotide LAR for patients with advanced gas..:

Ryan, P ; McBride, A ; Ray, D...
Journal of Oncology Pharmacy Practice. 25 (2019) 6 - p. 1425-1433 , 2019

Link: https://doi.org/10.1177/..

7

The development of a prediction tool to identify cancer pat..:

Dranitsaris, G. ; Molassiotis, A. ; Clemons, M....
Annals of Oncology. 28 (2017) 6 - p. 1260-1267 , 2017

Link: https://doi.org/10.1093/..

8

Evaluation of Progression-Free Survival as a Surrogate Endp..:

Adunlin, G ; Dranitsaris, G
Value in Health. 19 (2016) 3 - p. A170 , 2016

Link: https://doi.org/10.1016/..

9

A Multi-Criteria Decision Making Approach for Selecting an ..:

Adunlin, G ; Diaby, V ; Campbell, ES...
Value in Health. 19 (2016) 3 - p. A169-A170 , 2016

Link: https://doi.org/10.1016/..

10

Dalteparin Versus Vitamin K Antagonists for the Prevention ..:

Dranitsaris, G ; Shane, LG ; Woodruff, S..
Value in Health. 19 (2016) 3 - p. A154-A155 , 2016

Link: https://doi.org/10.1016/..

11

1590 Patient-related factors in determining the emetic risk..:

Aapro, M. ; Dielenseger, P. ; Dranitsaris, G....
European Journal of Cancer. 51 (2015) - p. S234 , 2015

Link: https://doi.org/10.1016/..

12

Economic Analysis of Lenalidomide/Dexamethasone (LEN/DEX) v..:

Shen, Z. ; King, J. ; Kaura, S....
Clinical Lymphoma Myeloma and Leukemia. 15 (2015) - p. e307 , 2015

Link: https://doi.org/10.1016/..

13

A randomized, double-blind, phase II, exploratory trial eva..:

Jacobs, C. ; Kuchuk, I. ; Bouganim, N....
Breast Cancer Research and Treatment. 155 (2015) 1 - p. 77-84 , 2015

Link: https://doi.org/10.1007/..

14

A comparison of toxicity and health care resource use betwe..:

Dranitsaris, G ; Beegle, N ; Kalberer, T...
Journal of Oncology Pharmacy Practice. 21 (2014) 3 - p. 170-177 , 2014

Link: https://doi.org/10.1177/..

15

Nab-Paclitaxel or Docetaxel as Alternatives to Solvent-Base..:

Dranitsaris, G. ; Yu, B. ; Qing, Z....
Value in Health. 17 (2014) 7 - p. A642 , 2014

Link: https://doi.org/10.1016/..